MarketPulse

South Korea

4 articles
BenzingaBenzinga··Prnewswire

Anixa Secures Korean Patent for Breast Cancer Vaccine, Bolstering IP Portfolio

Anixa Biosciences secures patent protection in South Korea for breast cancer vaccine technology, advancing its IP portfolio as Phase 1 trial shows 74% immune response rate.
ANIXintellectual propertyclinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Nxera Pharma Co., Ltd.

Nxera Pharma Pursues South Korea Insomnia Market With Daridorexant Filing

Nxera Pharma seeks South Korean approval for insomnia drug daridorexant, already marketed globally, with expected 2027 regulatory decision.
SGIOYPhase 3 trialregulatory approval
The Motley FoolThe Motley Fool··Brett Schafer

Coupang Stock Faces Headwinds but Maintains Growth Momentum

Coupang stock down 26% after data breach, but maintains 20% revenue growth and positive cash flow. Depressed valuation presents opportunity amid regulatory risks.
AMZNCPNGvaluatione-commerce
Investing.comInvesting.com··Mike Zaccardi, Cfa, Cmt

Emerging Market Equities Extend Outperformance Against U.S. Large-Cap Index

Emerging market equities significantly outperform U.S. large-cap stocks, with IEMG up 44% versus modest S&P 500 gains, driven by broad-based regional strength.
SPYEEMEWYEWZVWO+1emerging marketsoutperformance